After ACCORD, ADVANCE, and the VA Diabetes Trial, clinicians question intensive glucose control

For clinicians who treat patients with type 2 diabetes, tight glycemic control has long been a staple of good disease management. Results from the ACCORD, ADVANCE, and VA Diabetes Trial, all presented at this year’s American Diabetes Association Annual Meeting, however, have shaken up the current thinking about intensive glucose control. “My ‘religion’ for 30 years has been [that] the tighter the control the better,” said David S. H. Bell, MB, FACE, a professor of medicine at ...

FULL STORY